newsletter subscription

FREE COMMUNICATIONS

	Studio
09:00 - 09:55	Free Communications I. Chair: Klara Martinaskova, Katrien Smets
09:00 - 09:07	Sex disparities in pediatric patients and young adults with psoriasis treated with biologics: Differences in adverse events and disease activity Malak Al-Gawahiri
09:07 - 09:14	Dupilumab safety and efficacy up to 3 years in children aged 6 months to 11 years with severe atopic dermatitis Alan Irvine
09:14 - 09:21	Unlocking early intervention: Rapid non-invasive detection of Filaggrin mutations in infants Peter Caspers
09:21 - 09:28	Complementary analysis of local and systemic effects of dupilumab in pediatric AD using skin tape strips and serum Lisa Van Der Rijst
09:28 - 09:35	MissionEB -Mesenchymal intravenous stromal cell infusions in children with Recessive Dystrophic Epidermolysis Bullosa- a randomised, double-blinded, placebo controlled, cross-over trial Pablo Lopéz Balboa
09:35 - 09:42	EDELIFE: First pivotal study evaluating the benefit-risk ratio of a prenatal therapy for a genetic skin disease Smail Hadj-Rabia
09:42 - 09:49	Mosaic GNA11 and PIK3CA variants cause Blaschkolinear hypopigmentation Cathal O'Connor
09:49 - 09:55	Discussion

	Studio
10:00 - 10:55	Free Communications II. Chair: Marlies de Graaf, Justine Pêtre
10:00 - 10:07	Oleogel-S10 (birch triterpenes) for the treatment of pediatric patients with epidermolysis bullosa: Long-term data from the Phase 3 EASE Study Bruckner Anna
10:07 - 10:14	Severe mucocutaneous complications in pediatric Mycoplasma pneumoniae infections: Clinical characteristics and immunopathological insights Léa Jaume
10:14 - 10:21	Impact of 16 weeks of dupilumab treatment on height of children aged 6 to 11 years with severe atopic dermatitis Alan Irvine
10:21 - 10:28	Dupilumab-associated ocular surface disease in pediatric atopic dermatitis patients: Results from the BioDay registry Lisa Van Der Rijst
10:28 - 10:35	Updated integrated efficacy analysis of ritlecitinib up to 3 years in adolescents with alopecia areata from the ALLEGRO clinical trials Juliette Mazereeuw-Hautier
10:35 - 10:42	Trametinib therapy for congenital melanocytic naevi Cathal O'Connor
10:42 - 10:49	Diagnostic utility of optical genome mapping in genodermatoses Paola Merlo Gomez
10:49 - 10:55	Discussion

Address for official postal correspondence:

ESPD Office
c/o C-IN
5. kvetna 65, Prague Congress Centre
140 21 Prague 4
Czech Republic

Registered at:

1 Place de l'Hôpital
670 91 Strasbourg CEDEX
France

Office email address

office@espd.info

Office phone & fax numbers

Tel: +420 296 219 620

Follow us